-
6/14/2024
Rezolute，Inc.announced the pricing of its previously announced underwritten public offering of an aggregate of 11250000 shares of its common stock at an offering price of$4.00per share，and，to certain investors in lieu of common stock，pre-funded warrants to purchase up to 3750，000shares of common stock at an offering price of$3.999per pre-funded warrant。
-
6/14/2024
Enveda Biosciences，abiotechnology company using AI to translate nature into new medicines，announced anew financing round of$55 million to add to its$119million combined Series B and B1。
-
6/14/2024
Gain Therapeutics，Inc.announced the pricing of an underwritten public offering of 7116547 shares of its common stock at a public offering price of$1.35per share and pre-funded warrants to purchase1031602shares of common stock in lieu of common stock to certain investors。
-
6/14/2024
Ultragenyx Pharmaceutical Inc.，abiopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases，announced the pricing of its underwritten public offering of 7435898 shares of its common stock at a price to the public of 390。
-
6/14/2024
Greenwich LifeSciences，Inc.announced that it has entered into a securities purchase agement with its Chief Executive Officer，Snehal Patel，for the purchase and sale of 174，825 shares of its common stock at a purchase price of$14.30per share in a private placement。
-
6/14/2024
Avidity Biosciences，Inc.announced the pricing of an underwritten public offering of 10550000 shares of its common stock at a price to the public of$38.00per share。
-
With Versant Ventures as a founding investor，Santa Ana Bio emerged from stealth Thursday with$168 million in combined Series A and B funding to support plans to have two programs in the clinic by next year。
-
Among the biggest raises this year，Foresite Capital’s$900million fund will support biotech companies working in precision medicine and life science infrastructure。
-
6/13/2024
Scinai Immunotherapeutics Ltd.，abiotechnology company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit，announced that it has received anon-binding Letter of Intent from the European Innk。
-
6/13/2024
Gritstone bio，Inc.announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 6850 shares of its common stock with an exercise price of$0.75，which is equal to the closing price of Gritstone’s common stock on Je2027，the unte。
-
6/13/2024
Provectus Biopharmaceuticals，Inc.announced that its2024annual stockholder meeting，including meeting activities and a company update，will be accessible by Zoom Webinar。
-
6/13/2024
Conduit Pharmaceuticals Inc.，announced the Company is set to join the broad-market Russell3000®Index at the conclusion of the 2024 Russell US Indexes annual reconstitution，effective at the open of US equity markets on Monday，July12024，according to a preliminary list of additions posted by FTSE Russell on Friday，May24th，2024。
-
6/13/2024
Opus Genetics，a patient-first，clinical-stage gene therapy company developing treatments for inherited retinal diseases，announced it has received$1.7 million in project-based funding from the Foundation Fighting Blindness to help advance two preclinical candidate programs。
-
6/13/2024
Gain Therapeutics，Inc.announced that it is proposing to offer and sell，subject to market conditions，shares of its common stock in an underwritten public offering。
-
6/13/2024
Opthea Limited announced the successful completion of the institutional component of the capital raising announced on Wednesday，12June 2024。
-
6/13/2024
Genomma Lab Internacional，S.A.B.de C.V.informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of$0.200000 Mexican pesos per share on its common stock representing a total amount of$2000000.00M.N。， payable to shareholders of record of the applicable circulating shares at the close of business on June 212024。
-
6/13/2024
Carisma Therapeutics Inc.，aclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies，announced that the Company’s virtual annual meeting of stockholders held on June 132024 was convened and adjourned，withot any business being conducted， due to technical difficulties with the third-party hosting site。
-
6/13/2024
Vaxart，Inc.announced an underwritten offering of 50000000 shares of its common stock at an offering price of$0.80per share，which is a premium to the last closing price of$0.75per share。
-
6/13/2024
Enzo Biochem，Inc.announced financial results for the fiscal third quarter ended April302024。
-
6/13/2024
Rezolute，Inc.，a late-stage biopharmaceutical company committed to developing novel，transformative therapies for serious rare diseases，announced thatis commencing an underwritten public offering of shares of its common stock。
